Overview

Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis

Status:
Terminated
Trial end date:
2020-11-26
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to assess the efficacy and safety of two doses of vilaprisan compared to placebo in women with symptomatic endometriosis. The secondary objective of this study was to evaluate the safety and tolerability of two different doses of vilaprisan in women with symptomatic endometriosis. With the implementation of protocol amendment 6, no new subjects were enrolled. The objectives above cannot be reached as only limited data is available from subjects recruited before the temporary pause.
Phase:
Phase 2
Details
Lead Sponsor:
Bayer